Venture Investment in Health Care Sets Record in 2021

<p><strong>SANTA CLARA<&sol;strong> – Venture investment in healthcare reached new heights in 2021&comma; with more than &dollar;80 billion invested in biopharma&comma; medical device&comma; diagnostics&sol;tools &lpar;dx&sol;tools&rpar; and healthtech companies&comma; according to <a href&equals;"https&colon;&sol;&sol;www&period;svb&period;com&sol;">Silicon Valley Bank’s<&sol;a> annual <a href&equals;"https&colon;&sol;&sol;www&period;svb&period;com&sol;trends-insights&sol;reports&sol;healthcare-investments-and-exits&quest;utm&lowbar;source&equals;press-release&amp&semi;utm&lowbar;medium&equals;organic-social&amp&semi;utm&lowbar;campaign&equals;us-2022-01-aw-tl-na-na-lh-na&amp&semi;utm&lowbar;content&equals;lp&lowbar;na"><em>Healthcare Investments and Exits Report<&sol;em><&sol;a>&period;<&sol;p>&NewLine;<p>The more than 30&percnt; increase over 2020’s record is punctuated by a banner first half of the year&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Venture fundraising and investment in healthcare has continued at a torrid pace this year due to the great exit environment and lofty step ups in valuations&comma;” said report author Jon Norris&comma; Managing Director of SVB&&num;8217&semi;s Life Science and Healthcare Practice&period; &&num;8220&semi;With newly closed venture funds dedicated to healthcare this year&comma; there is a large pool of capital to support new investments and create a well-funded venture healthcare ecosystem for years to come&period;”<&sol;p>&NewLine;<p>SVB&&num;8217&semi;s annual report analyzes and predicts trends for venture capital investing&comma; fundraising and exits that shape the biopharma&comma; medical device&comma; diagnostics&sol;tools and healthtech sectors in the US and Europe&period;<&sol;p>&NewLine;<p><strong>Notable Results of 2021<&sol;strong>&colon;<&sol;p>&NewLine;<ul>&NewLine;<li>Healthcare venture fundraising nearly doubled 2020’s record at &dollar;28&period;3 billion&comma; providing a large pool of dedicated capital to support new investments in the coming years&period;<&sol;li>&NewLine;<li>All sectors saw records in investment activity&comma; highlighted by healthtech more than doubling 2020’s investment levels&comma; with later-stage &dollar;1B&plus; valuations surging to create 42 new unicorns in 2021 – more than 4x 2020’s total&period;<&sol;li>&NewLine;<li>Biopharma investment totaled &dollar;36B&comma; as Biopharma Seed&sol;Series A saw an outsized increase in anti-infective investment&period; There continued to be a drop in orphan and rare disease activity&period;<&sol;li>&NewLine;<li>Mega deals in dx&sol;tools tripled compared to 2020 with 38 &dollar;100M financings due to robust activity from late-stage investors&period;<&sol;li>&NewLine;<li>Early-stage device investment hit a record at &dollar;1&period;2B&comma; driven by &lpar;non-invasive monitoring&rpar; NIM investment&comma; which was up 92&percnt; over 2020&period;<&sol;li>&NewLine;<li>Overall&comma; deal investment declined slightly in the second half of the year as investors worked through a difficult public market environment&period;<&sol;li>&NewLine;<li>Venture healthcare exits also set records in 2021 with record IPO activity across every sector and private M&amp&semi;A records for healthtech&comma; dx&sol;tools and device sectors&period;<&sol;li>&NewLine;<&sol;ul>&NewLine;<p><strong>Outlook for 2022&colon;<&sol;strong><&sol;p>&NewLine;<p>&&num;8220&semi;Looking ahead to 2022&comma; we anticipate a slight decrease in fundraising and investment more closely mirroring the record levels seen in 2020&comma; as VCs prep their existing portfolio for exits but continue to invest recently-closed funds&comma;” said Norris&period;<&sol;p>&NewLine;<ul>&NewLine;<li>SVB expects venture fundraising to hit &dollar;16B and investment in companies to total &dollar;64B&period;<&sol;li>&NewLine;<li>Biopharma will likely see lower overall investment in the sector and a slowdown in IPO activity&period; However&comma; M&amp&semi;A should pick up in 2022 with a strong pace of private pre-clinical M&amp&semi;A continuing&period;<&sol;li>&NewLine;<li>Heathtech should see a continued strong year of M&amp&semi;A as SVB anticipates massive consolidation in this sector&period; Investments will be healthy but not at 2021 levels&period; The IPO market will remain open to more mature companies&period;<&sol;li>&NewLine;<li>In dx&sol;tools&comma; SVB estimates slightly fewer IPOs in 2022 and at lower valuations&period; Private M&amp&semi;A will remain strong with more than 20 deals predicted in 2022&period;<&sol;li>&NewLine;<li>SVB expects that investment in the device sector will decline as hybrid investors slow down mezzanine investing&period; M&amp&semi;A should continue to be robust&comma; but the IPO market will be more discerning&period;<&sol;li>&NewLine;<&sol;ul>&NewLine;

Editor

Wispr Scores $25 Million Series A Extension

SAN FRANCISCO -- Wispr, the voice-to-text AI that turns speech into clear, polished writing in every…

1 day

Numeric Dials Up $51 Million Series B

SAN FRANCISCO -- Numeric, an AI accounting automation platform, has raised a $51 million Series…

1 day

Apple Names 45 Finalists for App Store of the Year Awards

Apple has announced 45 finalists for this year’s App Store Awards, recognizing the best apps…

2 days

UC Reaches Agreement With Nurses, Strike Canceled

The University of California (UC) and the California Nurses Association (CNA) have reached a tentative…

4 days

HouseRX Rakes In $55 Million Series B

SAN FRANCISCO -- House Rx, a health tech company focused on making specialty medications more accessible and…

4 days

King Charles Honors NVIDIA’s Jensen Huang

Britain's King has given an award to the King of NVIDIA! NVIDIA founder and CEO…

4 days